Related references
Note: Only part of the references are listed.Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors
Lillian Sun et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2021)
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors
Noha Abdel-Wahab et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology
Sabrina Hoa et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
Kevin Tyan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
D. M. Barrios et al.
ANNALS OF ONCOLOGY (2021)
Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors
Paola Cutroneo et al.
DERMATOLOGIC THERAPY (2021)
Analysis of Matched Skin and Gut Microbiome of Patients with Vitiligo Reveals Deep Skin Dysbiosis: Link with Mitochondrial and Immune Changes
Hanene Bzioueche et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
Genetic Variants Predisposing Most Strongly to Type 1 Diabetes Diagnosed Under Age 7 Years Lie Near Candidate Genes That Function in the Immune System and in Pancreatic beta-Cells
Jamie R. J. Inshaw et al.
DIABETES CARE (2020)
Antibiotics Drive Microbial Imbalance and Vitiligo Development in Mice
Emilia R. Dellacecca et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Omar Hasan Ali et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency
Seiichi Yano et al.
EUROPEAN JOURNAL OF CANCER (2020)
Immune checkpoint inhibitors to treat cutaneous malignancies
Dulce M. Barrios et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Moving towards personalized treatments of immune-related adverse events
Khashayar Esfahani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Adrienne M. Luoma et al.
CELL (2020)
Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report
Harry Dang et al.
WORLD JOURNAL OF CLINICAL CASES (2020)
Gut Microbial Dysbiosis and Plasma Metabolic Profile in Individuals With Vitiligo
Qingrong Ni et al.
FRONTIERS IN MICROBIOLOGY (2020)
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Soyoung A. Oh et al.
NATURE CANCER (2020)
Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis
Omar Abdel-Rahman
IMMUNOTHERAPY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
Henry T. Quach et al.
JAMA ONCOLOGY (2019)
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S. Phillips et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immune dysregulation in cancer patients developing immune-related adverse events
Shaheen Khan et al.
BRITISH JOURNAL OF CANCER (2019)
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y. Lim et al.
CLINICAL CANCER RESEARCH (2019)
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
Y. Kanjanapan et al.
EUROPEAN JOURNAL OF CANCER (2019)
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Omar Hasan Ali et al.
EUROPEAN JOURNAL OF CANCER (2019)
Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin
Simone L. Park et al.
NATURE (2019)
Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics
Gregory S. Phillips et al.
JAMA DERMATOLOGY (2019)
Integrated miRNA and mRNA expression profiling identifies novel targets and pathological mechanisms in autoimmune thyroid diseases
Rebeca Martinez-Hernandez et al.
EBIOMEDICINE (2019)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Anu Sharma et al.
CLINICAL CANCER RESEARCH (2019)
The TYK2-P1104A Autoimmune Protective Variant Limits Coordinate Signals Required to Generate Specialized T Cell Subsets
Jacquelyn A. Gorman et al.
FRONTIERS IN IMMUNOLOGY (2019)
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
Esmee P. Hoefsmit et al.
ESMO OPEN (2019)
Exploration of shared genetic susceptibility loci between type 1 diabetes and rheumatoid arthritis in the Pakistani population
Muhammad Muaaz Aslam et al.
BMC RESEARCH NOTES (2019)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease RESPONSE
Noha Abdel-Wahab et al.
ANNALS OF INTERNAL MEDICINE (2018)
Staphylococcus aureus and atopic dermatitis: a complex relationship
O. Seddon et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
Francois-Xavier Danlos et al.
EUROPEAN JOURNAL OF CANCER (2018)
A transcriptomic signature predicting septic outcome in patients undergoing autologous stem cell transplantation
Yasmine Labiad et al.
EXPERIMENTAL HEMATOLOGY (2018)
Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration
Hansjorg Baurecht et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients
Gregory S. Phillips et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A20/Tumor necrosis Factor α-induced Protein 3 in immune Cells Controls Development of Autoinflammation and Autoimmunity: Lessons from Mouse Models
Tridib Das et al.
FRONTIERS IN IMMUNOLOGY (2018)
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
Beatriz Wills et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations
Khalaf Kridin et al.
FRONTIERS IN MEDICINE (2018)
Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy
Vincent Sibaud
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Jonathan L. Curry et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2017)
Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study
Yasuhiro Nakamura et al.
JOURNAL OF DERMATOLOGY (2017)
CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin
Stanley Cheuk et al.
IMMUNITY (2017)
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
Clelia Coutzac et al.
JOURNAL OF CROHNS & COLITIS (2017)
Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid
Laura Sowerby et al.
JAMA DERMATOLOGY (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Vivek Kumar et al.
FRONTIERS IN PHARMACOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice
John Foerster et al.
PLOS ONE (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
The Role of the Skin and Gut Microbiome in Psoriatic Disease
Di Yan et al.
CURRENT DERMATOLOGY REPORTS (2017)
Elevated semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis
Y. Du et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features
Michael T. Tetzlaff et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2017)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
Simone M. Goldinger et al.
CLINICAL CANCER RESEARCH (2016)
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
V. R. Belum et al.
EUROPEAN JOURNAL OF CANCER (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Tissue-resident memory T cells: local specialists in immune defence
Scott N. Mueller et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Elevated Semaphorin 5A correlated with Th1 polarization in patients with chronic immune thrombocytopenia
Mingen Lyu et al.
THROMBOSIS RESEARCH (2015)
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo et al.
JAMA DERMATOLOGY (2015)
Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy
Jennifer A. Lo et al.
JAMA ONCOLOGY (2015)
Secreted Semaphorin 5A Activates Immune Effector Cells and Is a Biomarker for Rheumatoid Arthritis
Christiane Gras et al.
ARTHRITIS & RHEUMATOLOGY (2014)
SDF-1-CXCR4 differentially regulates autoimmune diabetogenic T cell adhesion through ROBO1-SLIT2 interactions in mice
John D. Glawe et al.
DIABETOLOGIA (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Marcus Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Michelle A. Lowes et al.
TRENDS IN IMMUNOLOGY (2013)
A review of the worldwide prevalence of vitiligo in children/adolescents and adults
Christian Krueger et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2012)
Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
Julia K. Gittler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
CXCR3 ligands: redundant, collaborative and antagonistic functions
Joanna R. Groom et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
Effective Treatment of Psoriasis with Narrow-Band UVB Phototherapy Is Linked to Suppression of the IFN and Th17 Pathways
Emoke Racz et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
James D. Lord et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Autoantibodies against desmocollins in European patients with pemphigus
R. Mueller et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2009)
The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation
Meghan A. Koch et al.
NATURE IMMUNOLOGY (2009)
Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study
S. M. Langan et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics
Kristin K. Deeb et al.
NATURE REVIEWS CANCER (2007)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
KS Peggs et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Share Paper
